• Bicara Therapeutics CEO and director Claire Mazumdar cut her stake to 362,152 shares on May 18.
• The filing shows sales of 15,000 shares at weighted average prices of USD 19.96 and USD 20.35.
• She also acquired 15,000 shares at USD 3.79 through an option exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-036885), on May 20, 2026, and is solely responsible for the information contained therein.